Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism

Aim : To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S‐mephenytoin 4′‐hydroxylase (CYP2C19).

[1]  M. Vieth,et al.  Esomeprazole‐based one‐week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance , 2003, Alimentary pharmacology & therapeutics.

[2]  J. Gisbert,et al.  Meta‐analysis: comparative efficacy of different proton‐pump inhibitors in triple therapy for Helicobacter pylori eradication , 2003, Alimentary pharmacology & therapeutics.

[3]  B. Sheu,et al.  Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori , 2003, Alimentary pharmacology & therapeutics.

[4]  B. Sheu,et al.  Host gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2 genopositive infection , 2003, Gut.

[5]  B. Sheu,et al.  The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency , 2003, Alimentary pharmacology & therapeutics.

[6]  J. Hatlebakk.  Review article: gastric acidity − comparison of esomeprazole with other proton pump inhibitors , 2003, Alimentary pharmacology & therapeutics.

[7]  H. Kutsumi,et al.  Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1‐week regimen of proton pump inhibitor, amoxicillin and clarithromycin , 2003, Alimentary pharmacology & therapeutics.

[8]  N. Talley,et al.  A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. , 2002, Gastroenterology.

[9]  O. Junghard,et al.  The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH , 2002, European Journal of Clinical Pharmacology.

[10]  B. Sheu,et al.  Impact of supplement with Lactobacillus‐ and Bifidobacterium‐containing yogurt on triple therapy for Helicobacter pylori eradication , 2002, Alimentary pharmacology & therapeutics.

[11]  D. Passaro,et al.  Helicobacter pylori: consensus and controversy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  L. Laine.  Esomeprazole in the treatment of Helicobacter pylori , 2002 .

[13]  P. Malfertheiner,et al.  Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report , 2002, Alimentary pharmacology & therapeutics.

[14]  B. Sheu,et al.  Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding , 2002, Alimentary pharmacology & therapeutics.

[15]  T. Andersson,et al.  Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole , 2001, Alimentary pharmacology & therapeutics.

[16]  N. Talley,et al.  ESOMEPRAZOLE, A NEW PROTON PUMP INHIBITOR: PHARMACOLOGICAL CHARACTERISTICS AND CLINICAL EFFICACY , 2000, International journal of clinical practice.

[17]  J. Wu,et al.  Selection of Lower Cutoff Point of [13C]Urea Breath Test Is Helpful to Monitor H. pylori Eradication After Proton Pump Inhibitor-Based Triple Therapy , 2000, Digestive Diseases and Sciences.

[18]  H. Sugimura,et al.  Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. , 2000, Clinical pharmacology and therapeutics.

[19]  Williams,et al.  The effect of omeprazole dosing on the isolation of Helicobacter pylori from gastric aspirates , 1999, Alimentary pharmacology & therapeutics.

[20]  R. Spiller,et al.  The GU‐MACH study: the effect of 1‐week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer , 1999, Alimentary pharmacology & therapeutics.

[21]  O’morain,et al.  The DU‐MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy , 1999, Alimentary pharmacology & therapeutics.

[22]  R. Spiller,et al.  The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. , 1999, Gastroenterology.

[23]  R. Spiller,et al.  Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study , 1996, Helicobacter.

[24]  S. Higuchi,et al.  Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects , 1996 .

[25]  L. Bertilsson,et al.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. , 1995, British journal of clinical pharmacology.

[26]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[27]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[28]  T. Schubert,et al.  Patient factors affecting Helicobacter pylori eradication with triple therapy. , 1993, The American journal of gastroenterology.